Vor Biopharma Inc.
VOR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001817229
In the last 90 days, Vor Biopharma Inc. insiders filed 0 open-market purchases and 1 sale; 102 institutions reported holding it in 13F filings for Q2 2026, worth $893.0M in total; no superinvestor holds it.
Q1 2022 vs. Q4 2021
How the institutions holding Vor Biopharma Inc. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 61 | 58 | −3 |
| Shares | 31.2M | 31.1M | −63.2K (−0.2%) |
| Value | $362.0M | $187.9M | −$174.0M (−48.1%) |
New holders (9)
Institutions that held Vor Biopharma Inc. at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Bank of Montreal | 32,184 | $283.0K | 0.00% |
| LMR Partners LLP | 20,000 | $121.0K | 0.00% |
| Millennium Management LLC | 16,613 | $100.0K | 0.00% |
| Ergoteles LLC | 16,000 | $97.0K | 0.00% |
| Corton Capital Inc. | 10,795 | $65.0K | 0.03% |
| Barclays PLC | 3,083 | $19.0K | 0.00% |
| Amalgamated Bank | 2,380 | $14.0K | 0.00% |
| Amalgamated Financial Corp. | 2,380 | $14.0K | 0.00% |
| Federated Hermes, Inc. | 88 | $1.00K | 0.00% |
Sold out (12)
Institutions that held Vor Biopharma Inc. at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Gilder Gagnon Howe & Co LLC | 63,178 | $734.0K |
| Parkwood LLC | 39,372 | $458.0K |
| Parametric Portfolio Associates LLC | 21,650 | $252.0K |
| Susquehanna International Group, LLP | 12,360 | $144.0K |
| Manufacturers Life Insurance Company, The | 10,149 | $118.0K |
| MetLife Investment Management | 8,268 | $96.1K |
| UBS Group AG | 7,167 | $83.0K |
| Metropolitan Life Insurance Co | 6,255 | $72.7K |
| US Bancorp | 1,628 | $19.0K |
| Signaturefd, LLC | 587 | $7.00K |
| Parallel Advisors, LLC | 496 | $6.00K |
| Eagle Bay Advisors LLC | 150 | $2.00K |